Nivalis Therapeutics Wins Orphan Drug Status for CF Treatment

Nivalis Therapeutics has reeled in orphan drug designation for N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator protein.

The candidate works through a mechanism called S-nitrosoglutathione reductase inhibition, which is believed to control the unstable and defective cystic fibrosis transmembrane conductance regulator protein that is responsible for the disease.

Nivalis says it also will seek fast track status for the candidate.